Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 56 | ECE2018 | Next issue

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

Card image cap
ECE 2018, 19 - 22 May 2018; Barcelona, Spain

Symposia

New Aspects of Pituitary Regulation

ea0056s19.1 | New Aspects of Pituitary Regulation | ECE2018

Cytoskeleton, pharmacologic resistance and clinical aggressiveness in pituitary tumours

Mantovani Giovanna

Pituitary tumors, are mostly benign, but may cause significant morbidity in affected patients, including visual and neurologic manifestations from mass-effect, or endocrine syndromes caused by hormone hypersecretion. Dopamine (DA) receptor DRD2 and somatostatin (SS) receptors (SSTRs) represent the main targets of pharmacological treatment of pituitary tumors since they mediate inhibitory effects on both hormone secretion and cell proliferation, and their expression is retained...

ea0056s19.2 | New Aspects of Pituitary Regulation | ECE2018

What fat does with your pituitary

Malagon Maria M.

Adipose tissue is a highly active metabolic organ which, together with its classical role as energy storage depot, releases a wide variety of bioactive molecules with signaling properties, the adipokines, that play central roles in the regulation of energy metabolism and homeostasis, immunity and inflammation. Alterations in both adipokine production and lipid metabolism have been proposed to underlie the metabolic and cardiovascular disorders associated to excess body fat acc...

ea0056s19.3 | New Aspects of Pituitary Regulation | ECE2018

How cancer treatment effects your pituitary

Albarel Frederique

In recent years, immunotherapy has transformed the treatment in a number of cancers, including melanoma. It is associated with novel autoimmune side effects including endocrinopathies, among which hypophysitis (0.4–20% with Ipilimumab). We carried out a long-term study in endocrinology and dermatology departments of Marseille to characterise ipilimumab-induced hypophysitis in terms of clinical signs, endocrine profile and imaging, at diagnosis and during follow-up. Fiftee...